Phase 1 Trial of Icotinib Combined With Whole-Brain Radiation Therapy for EGFR-Mutated Non-Small Cell Lung Cancer Patients With Brain Metastases: Updated Results: Metastatic Non-Small Cell Lung Cancer

Abstract

Icotinib has been demonstrated to provide similar efficacy to gefitinib in non-small cell lung cancer (NSCLC) patients. This phase 1 trial (NCT01516983) evaluated the dose-escalation toxicities of icotinib combined with whole brain radiation therapy (WBRT) in EGFR-mutated NSCLC patients with brain metastases, and cerebrospinal fluid (CSF) penetration rates of icotinib were assessed in the dose-escalation.